- Olgram, a Brehan, France-based biotechnology company developing marine molecules for the prevention and control of bacterial infections, raised €1.5m in seed funding
- Olgram is a biotechnology company also developing marine molecules for the prevention and control of chronic bacterial infections
- The company has 2 product candidates targeting infections
- Olgram will first focus its efforts on cystic fibrosis, an orphan disease in which 35% of patients suffer from chronic Pseudomonas aeruginosa infections in adulthood leading to their premature death
- In a second phase, the company will target nosocomial infections in immunocompromised patients after head trauma
- The company also intends to use the funds to accelerate the development of anti-infectious molecules capable of eliminating the bacteria responsible for chronic relapses
